Lot-document scope confirmed before quotation · Research use only
  • Specification Review
  • Lot Documents on Request
  • Business Support · Xi’an
  • Destination Eligibility Confirmed
西安诺和达生物科技有限公司
For research, development and manufacturing use only. Not for human or veterinary use.

Healing & Tissue Repair · Source-reviewed dossier

Glow Peptide Blend

Source-Reviewed Research Dossier

Glow is a multi-component research blend involving peptides associated with skin and tissue-repair research. The studies listed here tested individual components or a two-component combination, not the complete Glow mixture. In a rat tendon experiment, combining BPC-157 with the material called TB-500 showed no added benefit. A small topical GHK-Cu study found no significant objective skin advantage, although questionnaire ratings were more favorable. These findings do not establish synergy, skin benefits or stability for the complete research blend.

Research use only Lot documents on request
Glow Peptide Blend research product family with 1 catalog variants
AI-generated packaging mockup for catalog navigation. It is not a photograph of an actual supplied lot; container, label and presentation may vary.

Product family

Compound overview

Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.

Product identity

Product type
Multi-component research blend
Catalog family
Glow Peptide Blend
Research category
Healing & Tissue Repair
Identity boundary
No single CAS, formula, sequence or molecular weight applies to this three-component formulation.
Evidence status
No directly matching controlled study; evidence is component-specific
Intended use
Research, development and manufacturing use only

Literature reference parameters

Compound or material class
TB-500 / BPC-157 / GHK multi-component blendCatalog-family identity
Evidence scope
No directly matching controlled study; evidence is component-specificDo not generalize beyond the cited model
Source review
Primary or authoritative records linked belowChecked 2026-09-01

Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.

Mechanism of action

How Glow Peptide Blend is studied

A target-to-pathway view grounded in the linked research records.

The blend itself has no direct study

The catalog item is a mixture of three peptides, but published research looks at each peptide alone or in pairs. A result for one peptide does not automatically apply to the mixture, because combining ingredients can change how stable or interactive the final blend is. No experiment has tested this exact three-part formulation, so researchers treat the individual peptide publications as background only, not as proof for the blend.

TB-500 and BPC-157 in rat tendon repair

In a rat study, the Achilles tendon was cut and then treated with TB-500, BPC-157, or both together for four weeks. TB-500 improved some mechanical strength measures. Both peptides improved some tissue appearance under the microscope. Combining them gave no extra benefit over either alone. This was an animal study, not in people, and the authors asked for dose testing and longer-term confirmation.

GHK-Cu as a topical skin cream

A small randomized study applied GHK-Cu skin-care products, which contain copper, after laser skin treatment on the face. Objective measures such as redness, wrinkles and overall skin quality showed no significant differences between groups. However, patients reported higher satisfaction with the GHK-Cu product. This was a cream applied to the skin, not an injection, and it does not confirm effects for an injectable or multi-peptide research blend.

Reported research findings

What published studies report about Glow Peptide Blend

Reported outcomes are paired with their experimental model and evidence boundary.

Component evidence

BPC-157 and TB-500 were tested together only in a rat tendon model

The 2026 rat study provides preclinical evidence for two components, not the additional GHK component or this catalog ratio.

No controlled evidence for the complete three-component blend is provided.

Read the primary study
Small topical study

GHK-Cu evidence is route- and formulation-specific

A small randomized topical study found no significant objective group differences on several assessed outcomes.

Topical GHK-Cu data cannot validate a multi-component injectable or research blend.

Read the primary study
Translation boundary: findings are limited to the evidence level stated on each card. Experimental protocol quantities are research details, not usage instructions.

Catalog options

Variant specifications

Pack-level catalog data; lot-level controls remain document-specific.

Catalog no.BBG70
Pack size70 mg × 10 vials
Current variant
Specification & documents for BBG70

Product specification

Multi-component research blend · 70 mg/vial catalog presentation · 10-vial pack · component identity and ratio controlled by product specification.

Lot documentation

Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.

Quality system

Quality documentation

A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.

Lot-specific Certificate of AnalysisAvailability and scope must be confirmed for the selected catalog variant and lot
COA availability unconfirmed Ask about availability
Product Specification SheetAvailability and scope must be confirmed for the selected catalog variant and lot
Confirm before ordering Request
Analytical Method SummaryAvailability and scope must be confirmed for the selected catalog variant and lot
Confirm before ordering Request

Analytical interpretation

Interpret the documents, not just the headline number.

Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.

Open the Quality & Documentation Hub

HPLC area ≠ assayA dominant peak does not establish target mass fraction.

Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.

Counterions affect contentWater, salt form and solvents change the as-is composition.

Storage needs a data basisShipping practice is not the same as stability evidence.

Evidence map

Research context

Published studies and regulatory records, not customer testimonials or usage guidance.

Component evidence

BPC-157 and TB-500 were tested together only in a rat tendon model

No controlled evidence for the complete three-component blend is provided.

View primary record
Small topical study

GHK-Cu evidence is route- and formulation-specific

Topical GHK-Cu data cannot validate a multi-component injectable or research blend.

View primary record
Evidence boundary: each card states its evidence type. Human trials and regulatory records describe the studied or regulated intervention; preclinical records remain model-specific. None verifies the identity, quality, safety or efficacy of this catalog lot or provides usage instructions.

Literature basis

Curated references

Third-party publications selected for direct relevance.

  1. 01

    Effects of BPC-157 and TB-500 on Achilles tendon healing in rats

    Biçer O, et al. Jt Dis Relat Surg. 2026;37:822–837. PMID 42542926.

    Randomized rat study
  2. 02

    Effects of topical copper tripeptide complex on laser-resurfaced skin

    Miller TR, et al. Archives of Facial Plastic Surgery. 2006. PMID 16847171.

    Human RCT

Research FAQ

Glow Peptide Blend questions

Concise answers for researchers comparing identity, evidence and catalog variants.

What effects are studied for Glow Peptide Blend?

TB-500 and BPC-157 were studied together in a rat tendon healing model, where TB-500 improved some mechanical measures and both improved some tissue appearance scores, but combining them added nothing extra. GHK-Cu was tested as a skin cream after laser treatment, with no significant objective differences but higher patient satisfaction. The exact three-peptide blend has no matching controlled study.

How should the Glow Peptide Blend research findings be understood?

A small randomized study applied GHK-Cu skin-care products, which contain copper, after laser skin treatment on the face. Objective measures such as redness, wrinkles and overall skin quality showed no significant differences between groups. However, patients reported higher satisfaction with the GHK-Cu product. This was a cream applied to the skin, not an injection, and it does not confirm effects for an injectable or multi-peptide research blend.

What evidence is available for Glow Peptide Blend?

Direct blend evidence is absent; the linked records establish the limits of available BPC/TB-500 and GHK research.

Does the cited research validate this catalog material?

No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.

Which quality documents can be requested?

A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.

How should Glow Peptide Blend be stored?

Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.

Knowledge tools

Continue with structured evidence

Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.

Internal technical source review

Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.

Editorial status: NHD evidence editorial workflow · 2026-09-01 · Not independent medical review · Review policy

Technical procurement

Ready to request a quote?

Selected: BBG70 · 70 mg × 10 vials